Logo Logo
Switch Language to German

Kern, Christoph; Fu, Dun Jack; Huemer, Josef; Faes, Livia; Wagner, Siegfried K.; Kortuem, Karsten; Patel, Praveen J.; Rajendram, Ranjan; Balaskas, Konstantinos; Hamilton, Robin; Sim, Dawn A. and Keane, Pearse A. (2020): An open-source data set of anti-VEGF therapy in diabetic macular oedema patients over 4 years and their visual acuity outcomes. In: Eye, Vol. 35, No. 5: pp. 1354-1364

Full text not available from 'Open Access LMU'.


Objectives: The objective of this paper is to evaluate visual acuity (VA) outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in diabetic macular oedema (DMO). Methods In this retrospective cohort study, electronic medical records for all patients undergoing intravitreal injections in a tertiary referral centre between March 2013 and October 2018 were analysed. Treatment response in terms of VA outcomes was reported for all eyes over a 4-year observation period. Results Our cohort includes 2614 DMO eyes of 1964 patients over 48 months. Cox proportional-hazards modelling identified injection number (hazard ratio (HR) = 1.18), male gender (HR = 1.13) and baseline VA (HR = 1.09) as independent predictors to reach a favourable visual outcome of more than 70 Early Treatment Diabetic Retinopathy Study letters. Half of our cohort reached 70 letters 1.9 months after starting anti-VEGF therapy. Of those that reached 70 letters, 50% fell below 70 letters by 14.7 months. Conclusion To date, this is the largest single centre cohort study and over the longest observation period reporting on real-life outcomes of anti-VEGF in DMO. We have made an anonymised version of our data set available on an open-source data repository as a resource for clinical researchers globally.

Actions (login required)

View Item View Item